Financial PerformanceSanthera's balance sheet appears healthy with potential runway through to cash flow breakeven, supported by expected top-line revenue growth.
Product LaunchThe European rollout of AGAMREE is accelerating, leading to an increase in the price target for Santhera Pharmaceuticals.
Regulatory ApprovalAGAMREE has received acceptance by Health Canada for the New Drug Submission with Priority Review, paving the way for it to become the first DMD drug approved in Canada.